Evoke Pharma (NASDAQ:EVOK) Now Covered by StockNews.com

Stock analysts at StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a note issued to investors on Saturday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Trading Down 3.0 %

Shares of EVOK opened at $2.25 on Friday. The company’s 50 day simple moving average is $4.05 and its 200-day simple moving average is $4.57. The firm has a market cap of $3.36 million, a PE ratio of -0.20 and a beta of 0.30. Evoke Pharma has a 12-month low of $2.19 and a 12-month high of $12.32.

Evoke Pharma (NASDAQ:EVOK) last posted its quarterly earnings data on Thursday, March 13th. The specialty pharmaceutical company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.24). Evoke Pharma had a negative net margin of 71.32% and a negative return on equity of 308.49%. The business had revenue of $3.31 million during the quarter, compared to analyst estimates of $3.08 million.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Evoke Pharma stock. Nantahala Capital Management LLC increased its stake in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) by 163.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 148,194 shares of the specialty pharmaceutical company’s stock after purchasing an additional 91,945 shares during the quarter. Nantahala Capital Management LLC owned 9.95% of Evoke Pharma worth $655,000 as of its most recent SEC filing.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.